Professional
Added to YB: 2025-04-11
Pitch date: 2025-04-08
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
-1.73%
current return
Author Info
No bio for this author
Company Info
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$108.3B
Pitch Price
$460.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
20.02
P/E
30.01
EV/Sales
8.37
Sector
Biotechnology
Category
growth
GreensKeeper Value Fund Portfolio Holding: Vertex Pharmaceuticals Incorporated
VRTX (holding update): +20.4% Q4. CF franchise driving FCF. Launched Alyftrek (CF, once-daily, 31 new mutations) & Journavx (non-opioid pain). Journavx potential blockbuster. Developing chronic pain therapies. Success could combat opioid crisis & boost shareholder value. Diversifying portfolio beyond CF.
Read full article (1 min)